You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
眾生藥業(002317.SZ):公司及子公司共有131個產品品規入選醫保目錄
格隆匯 12-05 18:41

格隆匯12月5日丨眾生藥業(002317.SZ)公佈,2021年12月3日,根據《國家醫保局人力資源社會保障部關於印發<國家基本醫療保險、工傷保險和生育保險藥品目錄(2021年)>的通知》(醫保發〔2021〕50號),公司及子公司共有131個產品品規入選《國家基本醫療保險、工傷保險和生育保險藥品目錄(2021年)》(以下簡稱"醫保目錄"),其中甲類70個,乙類61個。公司的核心產品複方血栓通膠囊、腦栓通膠囊、硫糖鋁口服混懸液、羧甲司坦口服溶液、鹽酸氮斯汀滴眼液、普拉洛芬滴眼液等繼續入選本次目錄。

公司核心產品複方血栓通膠囊為醫保目錄甲類品種,複方血栓通系列產品(片、顆粒、軟膠囊、滴丸)為醫保目錄乙類品種,在本次目錄中取消了支付範圍限制,提升了產品可及性和用藥公平性,惠及更多患者,公司產品將得到更廣泛的使用。公司繼續踐行"患者利益至上"的企業價值觀,提供優質產品和服務健康大眾,與行業共同穩健成長。

公司及子公司的產品繼續進入醫保目錄將得到更加廣泛的應用,將對公司產品拓展市場、擴大銷售以及公司長遠發展都將產生積極影響。按照國家政府部門的相關配套管理辦法,入選目錄產品可能面臨價格調整的風險。藥品未來的具體銷售情況可能受到市場環境變化等因素影響,對公司經營業績的影響暫無法估計,短期不會對公司的業績產生重大影響。敬請投資者注意投資風險。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account